読み込み中
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
前日終値
$0.4061
+$0.0479 · +13.37%
日中の時刻はETです。市場データは遅延する場合があります。
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
日中レンジ
現在 $0.4061
52週レンジ
現在 $0.4061
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
65
割安
センチメント
49
まちまち
リスク
74
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
日中レンジ
現在 $0.4061
52週レンジ
現在 $0.4061
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.55億 USD | 1.44億 USD | 1.27億 USD | 1.08億 USD | 8634.6万 USD |
| 売上原価 | 4134.7万 USD | 3864.8万 USD | 6510.5万 USD | 5487.4万 USD | 4602.1万 USD |
| 粗利益 | 1.14億 USD | 1.06億 USD | 6193.9万 USD | 5279.8万 USD | 4032.5万 USD |
| 研究開発 | 1242.9万 USD | 1668.3万 USD | 3913.3万 USD | 8270.4万 USD | 1.31億 USD |
| 販売・一般管理 | 1.04億 USD | 1億 USD | 1.2億 USD | 1.45億 USD | 1.27億 USD |
| 営業費用 | 1.16億 USD | 1.17億 USD | 1.73億 USD | 2.27億 USD | 2.58億 USD |
| 受取利息 | — | 355万 USD | 336.4万 USD | 163.8万 USD | 43.3万 USD |
| 支払利息 | — | 603.2万 USD | 386.8万 USD | 247.4万 USD | 241万 USD |
| 減価償却費と償却費 | 231.4万 USD | 249.2万 USD | 289.9万 USD | 288.9万 USD | 302.1万 USD |
| 営業利益 | −253.8万 USD | −1152.8万 USD | −1.11億 USD | −1.75億 USD | −2.18億 USD |
| 純利益 | −2019.5万 USD | −1358万 USD | −1.11億 USD | −1.82億 USD | −2.21億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$6.67
上昇余地（1542.45%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2014年1月13日 | 1:20 | — | — |
株式分割 | 2007年5月25日 | 1:4 | — | — |
発効済み 2014年1月13日
1:20
発効済み 2007年5月25日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI174.1万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM134.87万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF66.8万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO32.76万0.00%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO29.1万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC16.72万0.01%13.17億 USD0.60%$183+0.11%
Invesco NASDAQ Future Gen 200 ETFQQQS15.31万0.67%2275.83万 USD0.20%$42.145+1.39%
Vanguard Health Care ETFVHT10.41万0.00%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
